Linked Data API

Filter

These are the filters currently being used to limit the search results. Click on the remove filter icon to remove the filter.

house id	1
answering dept sort name	Health
hansard heading	Asthma: Drugs

Sort by

This list shows the properties that you can sort by. Click on to sort in ascending order and to sort in descending order. The properties that you're currently sorting by are shown at the top of the list. Click on remove this sort to remove a sort and or to reverse the current sort order. Click on the remove all sorting icon to remove all the sorting. Note that sorting can significantly slow down the loading of the page.

View

Choose what information you want to view about each item. There are some pre-defined views, but starred properties are always present no matter what the view. You can star properties by clicking on the icon. The currently starred icons have a icon; clicking on it will unstar the property.

Items per page

Choose how many items to view on each page. The more items you view, the longer the page will take to load.

Show Search Form

Search Results

registered interest

date

exactly:

or between:
and

answering body

answering dept id

answering dept short name

answering dept sort name

hansard heading

house id

legislature


pref label

question text

tabling member constituency

tabling member printed

uin

answer

is ministerial correction

date of answer

exactly:

or between:
and

answer text

answering member constituency

answering member printed

grouped question UIN

question first answered

question first ministerially corrected

answering member


label

previous answer version

answering member constituency

answering member printed

answering member


label

tabling member


label

100885

registered interest

date

24/10/2014

answering body

Department of Health

answering dept id

answering dept short name

Health

answering dept sort name

Health

hansard heading

Asthma: Drugs

house id

legislature

25259

	pref label	House of Commons

question text

To ask the Secretary of State for Health, how much the Government has spent on the development of new drugs to treat the symptoms of asthma in each of the last five years.

tabling member constituency

Leicester West

tabling member printed

Liz Kendall

uin

211885

answer

is ministerial correction

date of answer

29/10/2014

answer text

The following table shows estimated expenditure on research on asthma, motor neurone disease (MND) and osteoporosis by the Medical Research Council, other Research Councils and Innovate UK, and by the National Institute for Health (NIHR) through its research programmes, research centres and units, and research fellowships. £ million <table><tbody><tr><td> </td><td>2009-10</td><td>2010-11</td><td>2011-12</td><td>2012-13</td><td>2013-14</td></tr><tr><td colspan="6">Asthma</td></tr><tr><td>Medical Research Council</td><td><del class="ministerial">22.2 </del><ins class="ministerial">6.6</ins></td><td><del class="ministerial">17.5 </del><ins class="ministerial">5.3</ins></td><td><del class="ministerial">17.2</del><ins class="ministerial"> 4.5</ins></td><td><del class="ministerial">19.4</del><ins class="ministerial"> 3.6</ins></td><td><del class="ministerial">18.8</del><ins class="ministerial"> 5.4</ins></td></tr><tr><td>Other Research Councils and Innovate UK</td><td>0.0</td><td>0.1</td><td>0.3</td><td>1.5</td><td>0.8</td></tr><tr><td>National Institute for Health Research</td><td>2.6</td><td>3.4</td><td>2.4</td><td>3.4</td><td>3.8</td></tr><tr><td>Total</td><td><del class="ministerial">24.8</del><ins class="ministerial"> 9.2</ins></td><td><del class="ministerial">21.0</del><ins class="ministerial"> 8.8</ins></td><td><del class="ministerial">19.9</del><ins class="ministerial"> 7.2</ins></td><td><del class="ministerial">24.3 </del><ins class="ministerial">8.5</ins></td><td><del class="ministerial">23.4</del> <ins class="ministerial">10.0</ins></td></tr><tr><td colspan="6">Motor Neurone Research</td></tr><tr><td>Medical Research Council</td><td>7.0</td><td>7.5</td><td>4.2</td><td>4.1</td><td>3.6</td></tr><tr><td>Other Research Councils and Innovate UK</td><td>0.2</td><td>0.2</td><td>0.4</td><td>0.7</td><td>1.0</td></tr><tr><td>National Institute for Health Research</td><td>0.1</td><td>0.1</td><td>0.4</td><td>0.7</td><td>0.5</td></tr><tr><td>Total</td><td>7.3</td><td>7.8</td><td>5.0</td><td>5.5</td><td>5.1</td></tr><tr><td colspan="6">Osteoporosis</td></tr><tr><td>Medical Research Council</td><td>6.2</td><td>5.4</td><td>5.1</td><td>4.6</td><td>5.9</td></tr><tr><td>Other Research Councils and Innovate UK</td><td>0.0</td><td>0.0</td><td>0.1</td><td>0.4</td><td>1.0</td></tr><tr><td>National Institute for Health Research</td><td>0.3</td><td>0.7</td><td>0.8</td><td>1.3</td><td>1.8</td></tr><tr><td>Total</td><td>6.5</td><td>6.1</td><td>6.0</td><td>6.3</td><td>8.7</td></tr></tbody></table> The figures shown for asthma exclude research into air pollution and potential effects on health outcomes including asthma. Total spend by the NIHR on asthma, MND and osteoporosis is higher than the figures shown because expenditure by the NIHR Clinical Research Network (CRN) on these diseases cannot be disaggregated from total CRN expenditure. NIHR expenditure relating to development of new drugs for asthma, MND and osteroporosis occurs primarily through NIHR research infrastructure including the CRN and cannot be disaggregated from total expenditure. Information on MRC expenditure into the development of new drugs for asthma, MND or osteoporosis is not available.

answering member constituency

Mid Norfolk

answering member printed

George Freeman

question first answered

29/10/2014 17:12:29

question first ministerially corrected

13/11/2014 10:22:56

answering member

4020

	label	Biography information for George Freeman

previous answer version

25123

answering member constituency

Mid Norfolk

answering member printed

George Freeman

answering member

4020

	label	Biography information for George Freeman

tabling member

4026

	label	Biography information for Liz Kendall

100876

registered interest

date

24/10/2014

answering body

Department of Health

answering dept id

answering dept short name

Health

answering dept sort name

Health

hansard heading

Asthma: Drugs

house id

legislature

25259

	pref label	House of Commons

question text

To ask the Secretary of State for Health, how much has been spent on the prescription of asthma drugs in the NHS in each of the last five years.

tabling member constituency

Leicester West

tabling member printed

Liz Kendall

uin

211846

answer

is ministerial correction

date of answer

29/10/2014

answer text

Information on National Health Service expenditure on drugs for the treatment of asthma in primary and secondary care is in the table. Drugs for the treatment of osteoporosis have been defined as those included in the following British National Formulary sections: 3.1.1 Adrenoceptor agonists 3.1.2 Antimuscarinic bronchodilators 3.1.3 Theophylline 3.2 Corticosteroids 3.3.1 Cromoglicate and related therapy 3.3.2 Leukotriene receptor antagonists 3.4.2 Allergen immunotherapy (omalizumab only) <table><tbody><tr><td colspan="11">Cost of drugs for the treatment of asthma, England1</td></tr><tr><td rowspan="2">Drug name</td><td colspan="5">Primary Care (£ millions)</td><td colspan="5">Secondary Care (£ millions)</td></tr><tr><td>2009</td><td>2010</td><td>2011</td><td>2012</td><td>2013</td><td>2009</td><td>2010</td><td>2011</td><td>2012</td><td>2013</td></tr><tr><td>Aclidinium Bromide</td><td>-</td><td>-</td><td>-</td><td>0.02</td><td>1.62</td><td>-</td><td>-</td><td>-</td><td>0.00</td><td>0.03</td></tr><tr><td>Aminophylline</td><td>1.25</td><td>1.18</td><td>1.12</td><td>1.08</td><td>1.05</td><td>0.30</td><td>0.29</td><td>0.21</td><td>0.23</td><td>0.22</td></tr><tr><td>Beclometasone Dipropionate</td><td>84.26</td><td>87.72</td><td>90.30</td><td>97.56</td><td>102.39</td><td>1.62</td><td>1.53</td><td>1.41</td><td>1.49</td><td>1.42</td></tr><tr><td>Budesonide</td><td>140.35</td><td>149.03</td><td>158.82</td><td>169.14</td><td>177.00</td><td>1.29</td><td>1.14</td><td>1.14</td><td>1.27</td><td>1.41</td></tr><tr><td>Budesonide/ Formoterol</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>2.75</td><td>2.94</td><td>2.89</td><td>3.10</td><td>3.29</td></tr><tr><td>Ciclesonide</td><td>0.84</td><td>0.95</td><td>1.03</td><td>1.12</td><td>1.25</td><td>0.01</td><td>0.02</td><td>0.02</td><td>0.02</td><td>0.03</td></tr><tr><td>Fluticasone</td><td>366.24</td><td>380.56</td><td>387.89</td><td>392.95</td><td>396.10</td><td>1.00</td><td>0.93</td><td>0.91</td><td>1.00</td><td>0.99</td></tr><tr><td>Fluticasone/ Salmeterol</td><td>-</td><td>-</td><td>-</td><td>-</td><td>-</td><td>11.46</td><td>11.56</td><td>10.69</td><td>10.82</td><td>10.48</td></tr><tr><td>Formoterol Fumarate</td><td>5.18</td><td>4.87</td><td>4.68</td><td>4.85</td><td>4.93</td><td>0.10</td><td>0.08</td><td>0.07</td><td>0.06</td><td>0.06</td></tr><tr><td>Glycopyrronium Bromide</td><td>-</td><td>-</td><td>-</td><td>0.01</td><td>2.30</td><td>0.58</td><td>0.62</td><td>0.70</td><td>0.79</td><td>1.00</td></tr><tr><td>Indacaterol Maleate</td><td>-</td><td>0.04</td><td>0.30</td><td>0.92</td><td>1.47</td><td>-</td><td>0.00</td><td>0.00</td><td>0.02</td><td>0.04</td></tr><tr><td>Ipratropium Bromide</td><td>16.15</td><td>15.02</td><td>13.74</td><td>10.32</td><td>8.61</td><td>2.74</td><td>2.84</td><td>2.59</td><td>2.65</td><td>2.70</td></tr><tr><td>Mometasone Furoate</td><td>0.36</td><td>0.31</td><td>0.26</td><td>0.23</td><td>0.21</td><td>0.76</td><td>0.71</td><td>0.61</td><td>0.63</td><td>0.67</td></tr><tr><td>Montelukast</td><td>38.91</td><td>43.01</td><td>46.96</td><td>51.71</td><td>31.31</td><td>0.98</td><td>1.02</td><td>1.03</td><td>1.16</td><td>0.81</td></tr><tr><td>Omalizumab</td><td>0.00</td><td>0.01</td><td>0.03</td><td>0.15</td><td>0.12</td><td>5.97</td><td>9.22</td><td>12.16</td><td>14.65</td><td>17.86</td></tr><tr><td>Salbutamol</td><td>83.15</td><td>82.64</td><td>60.58</td><td>60.37</td><td>59.95</td><td>3.78</td><td>3.77</td><td>3.36</td><td>3.38</td><td>3.29</td></tr><tr><td>Salmeterol</td><td>48.80</td><td>45.16</td><td>41.87</td><td>36.72</td><td>34.04</td><td>0.87</td><td>0.74</td><td>0.59</td><td>0.53</td><td>0.47</td></tr><tr><td>Terbutaline Sulphate</td><td>8.61</td><td>8.20</td><td>7.61</td><td>7.43</td><td>7.18</td><td>0.18</td><td>0.16</td><td>0.14</td><td>0.14</td><td>0.15</td></tr><tr><td>Theophylline</td><td>2.18</td><td>2.17</td><td>2.15</td><td>2.22</td><td>2.26</td><td>0.12</td><td>0.11</td><td>0.11</td><td>0.11</td><td>0.11</td></tr><tr><td>Tiotropium</td><td>113.61</td><td>129.98</td><td>149.81</td><td>169.35</td><td>185.24</td><td>5.69</td><td>6.03</td><td>6.22</td><td>6.64</td><td>6.87</td></tr><tr><td>Zafirlukast</td><td>0.79</td><td>0.71</td><td>0.71</td><td>0.70</td><td>0.69</td><td>0.01</td><td>0.01</td><td>0.01</td><td>0.01</td><td>0.01</td></tr><tr><td>Other drugs2</td><td>0.90</td><td>0.79</td><td>0.66</td><td>0.62</td><td>0.60</td><td>0.04</td><td>0.07</td><td>0.15</td><td>0.26</td><td>0.46</td></tr><tr><td>Total</td><td>911.6</td><td>952.3</td><td>968.5</td><td>1,007.5</td><td>1,018.3</td><td>40.3</td><td>43.8</td><td>45.0</td><td>49.0</td><td>52.4</td></tr></tbody></table> 1 Cost of drugs at NHS list price not taking account of discounts, dispensing costs, fees or prescription charges income. Totals may not add up due to rounding. 2 Other drugs include Azelastine/Fluticasone, Bambuterol Hydrochloride, Beclometasone/ Formoterol, Cromoglicic Acid, Fenoterol Hydrobromide, Fenoterol/Ipratropium Bromide, Fluticasone/ Formoterol, Nedocromil Sodium, Orciprenaline Sulfate and Sodium Cromoglicate. Source: Prescription Cost Analysis (PCA) provided by the Health and Social Care Information Centre (primary care) Hospital Pharmacy Audit Index (HPAI) provided by IMS Health (secondary care) Since some drugs are prescribed to treat more than one condition and as the condition for which a drug is prescribed is not collected, it is not possible to separate the different conditions for which a drug may have been prescribed. The information provided may therefore include costs from the prescribing of these drugs for conditions other than for asthma.

answering member constituency

Mid Norfolk

answering member printed

George Freeman

question first answered

29/10/2014 17:13:01

answering member

4020

	label	Biography information for George Freeman

tabling member

4026

	label	Biography information for Liz Kendall

381490

registered interest

date

16/06/2015

answering body

Department of Health

answering dept id

answering dept short name

Health

answering dept sort name

Health

hansard heading

Asthma: Drugs

house id

legislature

25259

	pref label	House of Commons

question text

To ask the Secretary of State for Health, what discussions he has had with (a) the British Medical Association and (b) other medical bodies on possible adverse effects of the use of inhalers for the treatment of asthma.

tabling member constituency

Strangford

tabling member printed

Jim Shannon

uin

2670

answer

is ministerial correction

date of answer

24/06/2015

answer text

There have been no recent discussions between the Secretary of State and the British Medical Association or other medical bodies on possible adverse effects of the use of inhalers for the treatment of asthma.

answering member constituency

Battersea

answering member printed

Jane Ellison

question first answered

24/06/2015 11:21:35

answering member

3918

	label	Biography information for Jane Ellison

tabling member

4131

	label	Biography information for Jim Shannon

386284

registered interest

date

29/06/2015

answering body

Department of Health

answering dept id

answering dept short name

Health

answering dept sort name

Health

hansard heading

Asthma: Drugs

house id

legislature

25259

	pref label	House of Commons

question text

To ask the Secretary of State for Health, what assessment he has made of the cost effectiveness of prescribing medicines for asthma patients; and if he will make a statement.

tabling member constituency

South Down

tabling member printed

Ms Margaret Ritchie

uin

4661

answer

is ministerial correction

date of answer

02/07/2015

answer text

We have made no such assessment. The National Institute for Health and Care Excellence (NICE) is responsible for providing guidance to the National Health Service on the clinical and cost effectiveness of selected drugs and indications through its technology appraisal programme. NICE has published several pieces of technology appraisal guidance covering a number of different technologies for use in the treatment of adults and children with asthma. Further information is available on NICE’s website at: <a href="http://www.nice.org.uk/guidance/conditions-and-diseases/respiratory-conditions/asthma" target="_blank">www.nice.org.uk/guidance/conditions-and-diseases/respiratory-conditions/asthma</a>

answering member constituency

Mid Norfolk

answering member printed

George Freeman

question first answered

02/07/2015 12:15:21

answering member

4020

	label	Biography information for George Freeman

tabling member

4130

	label	Biography information for Baroness Ritchie of Downpatrick

514073

registered interest

date

19/04/2016

answering body

Department of Health

answering dept id

answering dept short name

Health

answering dept sort name

Health

hansard heading

Asthma: Drugs

house id

legislature

25259

	pref label	House of Commons

question text

To ask the Secretary of State for Health, how much was spent by the NHS on asthma drugs in each year since 2010.

tabling member constituency

Halton

tabling member printed

Derek Twigg

uin

34586

answer

is ministerial correction

date of answer

25/04/2016

answer text

Information on National Health Service expenditure on drugs for the treatment of asthma1 in primary and secondary care is shown in the table. Since some drugs are prescribed to treat more than one condition and as the condition for which a drug is prescribed is not collected, it is not possible to specify the different conditions for which a drug may have been prescribed. The information provided may therefore include costs from the prescribing of drugs that treated conditions other than asthma. <table><tbody><tr><td colspan="4">Cost of drugs for the treatment of asthma, England2</td></tr><tr><td>Year</td><td>Primary care (£ millions)</td><td>Secondary care (£ millions)</td><td>Combined total (£ millions)</td></tr><tr><td>2010</td><td>952.4</td><td>43.9</td><td>999.3</td></tr><tr><td>2011</td><td>968.5</td><td>45.1</td><td>1,013.6</td></tr><tr><td>2012</td><td>1,007.5</td><td>49.0</td><td>1,056.5</td></tr><tr><td>2013</td><td>1,018.3</td><td>52.4</td><td>1,070.7</td></tr><tr><td>2014</td><td>1,031.2</td><td>56.1</td><td>1,087.2</td></tr><tr><td>2015 3</td><td>1,039.4</td><td>-</td><td>-</td></tr></tbody></table> Sources: Prescription Cost Analysis (PCA) system data provided by the Health and Social Care Information Centre (primary care). Hospital Pharmacy Audit Index (HPAI) provided by IMS Health (secondary care). Notes:1 Drugs for the treatment of asthma have been defined as those included in the following British National Formulary (BNF) sections, using the classification system prior to edition 70:3.1.1 Adrenoceptor agonists3.1.2 Antimuscarinic bronchodilators3.1.3 Theophylline3.2 Corticosteroids3.3.1 Cromoglicate and related therapy3.3.2 Leukotriene receptor antagonists3.4.2 Allergen immunotherapy (omalizumab only)2 Cost of drugs at NHS list price not taking account of discounts, dispensing costs, fees or prescription charges income. Totals may not add up due to rounding.3 Secondary care data for 2015 is not yet available.

answering member constituency

Mid Norfolk

answering member printed

George Freeman

question first answered

25/04/2016 13:04:35

answering member

4020

	label	Biography information for George Freeman

tabling member

429

	label	Biography information for Derek Twigg

58255

registered interest

date

05/06/2014

answering body

Department of Health

answering dept id

answering dept short name

Health

answering dept sort name

Health

hansard heading

Asthma: Drugs

house id

legislature

25259

	pref label	House of Commons

question text

To ask the Secretary of State for Health, if he will abolish prescription charges for asthma medication.

tabling member constituency

Cambridge

tabling member printed

Dr Julian Huppert

uin

199363

answer

is ministerial correction

date of answer

12/06/2014

answer text

The list of medical conditions conferring exemption from prescription charges in England was agreed with the medical profession in 1968. The only addition to the list was the introduction of cancer in 2009. Professor Sir Ian Gilmore, then President of the Royal College of Physicians, was asked in 2008, to consider how this might be extended to cover all those with a long term condition. The Department published his report in May 2010. In the light of the challenging financial context, the Government made clear in the Spending Review, published in October 2010, that no changes would be made to the current list of medical exemption. Prescription charges in England raise valuable income, in the region of £450 million each year, which helps the National Health Service to maintain vital services for patients. An extensive system of exemption arrangements, including for those on low incomes who may struggle to pay for their prescriptions, is in place which means that around 90% of all prescription items are already dispensed free of charge. Prescription Prepayment Certificates (PPCs) are also available for those who have to pay NHS prescription charges and need multiple prescriptions. This is the fifth year the cost of an annual certificate, and the third year the cost of a three month certificate, have been frozen. Both certificates will also remain at £104 and £29.10 respectively, next year. There is no limit to the number of items that can be obtained through a PPC. The annual certificate benefits anyone needing more than 12 items a year, and the three month certificate anyone needing more than three items in that three month period.

answering member constituency

North Norfolk

answering member printed

Norman Lamb

grouped question UIN

199364

question first answered

12/06/2014 14:36:47

answering member

1439

	label	Biography information for Norman Lamb

tabling member

3931

	label	Biography information for Dr Julian Huppert